Actinium Pharmaceuticals is currently recruiting patients with Relapsed/Refractory (RR) multiple myeloma for a Phase I clinical trial to study the safety and efficacy of the drug lintuzumab in combination with actinium-225.
Lintuzumab is a humanized monoclonal antibody that has was originally developed for the treatment of Acute Myeloid Leukemia (AML). Lintuzumab targets the CD33 cell surface protein, that is present in about one-third of multiple myeloma patients but is more prevalent in patients with refractory/relapsed disease. Actinium is one of the first radioactive compounds that was isolated in the early 1900’s and is only found in traces of uranium and thorium ore. In nature, it appears as actinium with 227 isotopes. Actinium-227 is converted in the lab to actinium-225 (Ac-225) and it is this element that has been used in medicine as a radionucleotide generator of alpha particles for targeted therapies.
The company explains that lintuzumab will ‘latch on’ to the CD33 protein of the cancerous cell which will then be ‘shot’ with minute doses alpha particles from the Ac-225 to kill the cancerous cell without damaging surrounding healthy cells. This combination is being studied in ‘patients who have progressing disease after 3 prior multiple myeloma treatment regimens or are refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, Dexamethasone)’.
To learn more or to join this trial, click here.